Impact of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population

Wednesday, April 25, 2018
Cover image
Mark Tesell, PharmD, BCPS
University of Massachusetts Medical School
Karen Stevens, PharmD.
University of Massachusetts Medical School
Bonnie Greenwood, PharmD, BCPS
University of Massachusetts Medical School
Caroline J. Alper, MD
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School

This poster gives an overview of pulmonary exacerbation rates pre- and post-initiation of Lumacaftor/Ivacaftor (LUM/IVA) in Massachusetts' Medicaid program. Pulmonary disease is one of the leading causes of morbidity and mortality among patients with cystic fibrosis. LUM/IVA has been effective in improving pulmonary outcomes in two observational studies, but before this study, there had been no published data evaluating real-world outcomes for Medicaid patients receiving this therapy. 

This poster on the impact of a drug for patients with cystic fibrosis was shared during the 2018 Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting and awarded a gold ribbon. The poster abstracts were evaluated on relevance, originality, quality, bias and clarity. Only 20 percent of submitted abstracts were honored with awards.

Conference 
2018 Managed Care & Specialty Pharmacy Annual Meeting